Population pharmacokinetics of amikacin in patients with pediatric cystic fibrosis.
Paulo Caceres GuidoMariel PerezAlicia HalacMariela FerrariManuel IbarraNieves LicciardoneClaudio CastañosLuis P GravinaCristina JimenezFacundo Garcia BournissenPaula SchaiquevichPublished in: Pediatric pulmonology (2019)
The regimen of 30 mg-1 kg-1 day-1 every 24 hours more adequately fulfilled the therapeutic target for amikacin. Although all our patients had good clinical results and a good adverse-events profile, further studies are necessary to redefine the optimal treatment strategy.